Trial Profile
Acalabrutinib Plus RICE for Patients With Relapsed/Refractory DLBCL Followed by Autologous Hematopoietic Cell Transplantation and Acalabrutinib Maintenance Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Carboplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Rituximab (Primary) ; Carmustine; Cytarabine; Melphalan
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 13 Dec 2022 Primary endpoint has been met (Cohort A: Complete Response Rate), as per Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 20 Jul 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.